{"data":{"id":955,"lang":"en","title":"FDA Approves High-Dose Wegovy With 20.7% Weight Loss, First Drug Fast-Tracked Under New Priority Voucher","summary":"FDA approves tripled-dose Wegovy showing 20.7% weight loss, the first drug cleared under the new priority voucher fast-track program.","category":"science","category_label":"Science","published_at":"2026-03-21T22:02:14Z","updated_at":"2026-03-21T22:02:14Z","url":"https://techtools.cz/tools/news/article/955-fda-approves-high-dose-wegovy-with-20-7-weight-loss-first-drug-fast-tracked","api_url":"https://techtools.cz/news-api/v1/articles/955?lang=en","markdown_url":"https://techtools.cz/news-api/v1/articles/955.md?lang=en","image_url":"https://www.sciencealert.com/images/2026/03/person-holds-injector.jpg","word_count":127,"reading_time_minutes":1,"sources":[{"url":"https://www.cnbc.com/2026/03/19/fda-approves-high-dose-version-of-novo-nordisks-obesity-drug-wegovy.html","domain":"cnbc.com"},{"url":"https://www.sciencealert.com/fda-approves-new-high-dose-wegovy-in-us-for-boosted-weight-loss","domain":"sciencealert.com"}],"translation":{"lang":"cs","id":988,"title":"FDA schválila vysokodávkové Wegovy s úbytkem hmotnosti 20,7 %, první lék zrychlený novým prioritním programem","url":"https://techtools.cz/tools/news/clanek/988-fda-schvalila-vysokodavkove-wegovy-s-ubytkem-hmotnosti-20-7-prvni-lek-zrychleny","api_url":"https://techtools.cz/news-api/v1/articles/988?lang=cs"},"content":"The FDA approved Novo Nordisk's higher-dose 7.2 mg Wegovy injection on March 19, tripling the previous maximum dose of 2.4 mg. In a phase 3 trial, patients with obesity lost an average of 20.7% of their body weight after 72 weeks, while those with obesity and Type 2 diabetes lost 14.1%.\n\nThe approval marks the first use of the FDA's new national priority voucher program, which cuts drug review times to one to two months. Novo Nordisk plans to launch the higher dose in April as it fights to reclaim market share from Eli Lilly's competing GLP-1 drugs.\n\nSide effects were reported in over 70% of patients on the high dose, including nausea, vomiting, and constipation, compared to 60% on the standard dose and 43% on placebo."}}